Niaspan is owned by Abbvie.

Niaspan contains Niacin.

Niaspan has a total of 9 drug patents out of which 9 drug patents have expired.

Expired drug patents of Niaspan are:

• US7011848
• US6676967
• US6406715
• US6746691
• US6129930
• US6818229
• US7998506
• US6080428
• US6469035

Niaspan was authorised for market use on 28 July, 1997.

Niaspan is available in tablet, extended release;oral dosage forms.

Niaspan can be used as intermediate rel nicotinic acid formulations having unique urinary metab profiles resulting from absorption profiles of nicotinic acid from the intermediate nicotinic acid formulations,suitable for tx hyperlipidemia following qd dosing, an intermediate release nicotinic acid formulation suitable for oral administration once-a-day as a single dose for treating hyperlipidemia without causing drug-induced hepatotoxicity or elevations in uric acid or glucose or both, reduction in tg by dosing once per day in the evening or at night, reduction in risk of recurrent nonfatal myocardial infarction by dosing once per day in the evening or a t night, with pretreatment with a flush inhibiting agent such as aspirin, reduction in risk of recurrent nonfatal myocardial infarction by dosing once per day in the evening or at night, treatment of primary and mixed dyslipidemia by dosing once per day in the evening or at night.

The generics of Niaspan are possible to be released after 15 March, 2018.